Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors

• Published in: AIDS (London) Vol. 38; no. 12; pp. 1758 - 1764
• Main Authors: Russo, Samuel C, Ockene, Mollie W, Arpante, Allison K, Johnson, Julia E, Lee, Hang, Toribio, Mabel, Stanley, Takara L, Hadigan, Colleen M, Grinspoon, Steven K, Erlandson, Kristine M, Fourman, Lindsay T
• Format: Journal Article
• Language: English
• Published: England 01.10.2024
• Subjects: Absorptiometry, Photon; Adult; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Growth Hormone-Releasing Hormone - analogs & derivatives; Growth Hormone-Releasing Hormone - antagonists & inhibitors; Growth Hormone-Releasing Hormone - therapeutic use; HIV Infections - complications; HIV Infections - drug therapy; HIV Integrase Inhibitors - adverse effects; HIV Integrase Inhibitors - therapeutic use; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Placebos - administration & dosage; Treatment Outcome

Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). Phase III clinical trials were conducted prior to the introduction of integrase inhibitors (INSTIs), which are now a mainstay of HIV antiretroviral therapy. We leveraged a randomized double-bli...